Further, we cleared M2 macrophages with anti-CD163 antibody (Fig. 1J) to analyze whether RNASEH2C was dependent on M2 macrophages for its cancer-promoting effects and found both Rnaseh2c-cKO and this antibody inhibited tumor growth and extended survival, with Rnaseh2c-cKO still effective in mice lacking M2 macrophages (Fig. 1K-O). Here, CD163 is linked to neoplasm.